Deals In Depth: June/July 2012
Executive Summary
Walgreen took a 45% stake in Alliance Boots for $6.6 billion. BMS boosted its diabetes portfolio by paying $6.8 billion for Amylin, while German device manufacturer BSN Medical was bought out by EQT for $2.2 billion. Biopharma financing totaled $713 million and $1.3 billion in June and July, respectively. Device fundraising decreased, going from $352 million in June to $126 million the following month.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.